CCNG2

Summary

CCNG2 (cyclin G2, HGNC:1593) is a protein-coding gene on chromosome 4q21.1, encoding Cyclin-G2 (Q16589). May play a role in growth regulation and in negative regulation of cell cycle progression.

The eukaryotic cell cycle is governed by cyclin-dependent protein kinases (CDKs) whose activities are regulated by cyclins and CDK inhibitors. The 8 species of cyclins reported in mammals, cyclins A through H, share a conserved amino acid sequence of about 90 residues called the cyclin box. The amino acid sequence of cyclin G is well conserved among mammals. The nucleotide sequence of cyclin G1 and cyclin G2 are 53% identical. Unlike cyclin G1, cyclin G2 contains a C-terminal PEST protein destabilization motif, suggesting that cyclin G2 expression is tightly regulated through the cell cycle.

Source: NCBI Gene 901 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 53 total
• MANE Select transcript: NM_004354

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1593
Approved symbol	CCNG2
Name	cyclin G2
Location	4q21.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000138764
Ensembl biotype	protein_coding
OMIM	603203
Entrez	901

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000316355, ENST00000395640, ENST00000497512, ENST00000502280, ENST00000509972, ENST00000512918, ENST00000514756, ENST00000863383, ENST00000863384, ENST00000863385, ENST00000957897

RefSeq mRNA: 1 — MANE Select: NM_004354 NM_004354

CCDS: CCDS3581

Canonical transcript exons

ENST00000316355 — 8 exons

Exon	Start	End
ENSE00001275225	77165801	77170060
ENSE00001864532	77157207	77157506
ENSE00003527254	77160721	77160971
ENSE00003563962	77159367	77159504
ENSE00003581563	77161649	77161747
ENSE00003632653	77164274	77164479
ENSE00003652129	77161480	77161558
ENSE00003756504	77158533	77158670

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.68.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.7140 / max 490.8687, expressed in 1762 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
48404	8.4507	1703
48405	2.3969	1121
48406	1.5658	505
48408	1.0729	377
48409	0.1545	58
48410	0.0396	13
48407	0.0337	15

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amniotic fluid	UBERON:0000173	99.68	gold quality
esophagus squamous epithelium	UBERON:0006920	99.29	gold quality
germinal epithelium of ovary	UBERON:0001304	99.16	gold quality
parietal pleura	UBERON:0002400	99.00	gold quality
tibia	UBERON:0000979	98.84	gold quality
epithelium of esophagus	UBERON:0001976	98.75	gold quality
visceral pleura	UBERON:0002401	98.68	gold quality
lower esophagus mucosa	UBERON:0035834	98.68	gold quality
pleura	UBERON:0000977	98.34	gold quality
oral cavity	UBERON:0000167	98.30	gold quality
cerebellar vermis	UBERON:0004720	98.22	gold quality
epithelium of nasopharynx	UBERON:0001951	98.18	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.18	gold quality
mammary duct	UBERON:0001765	97.87	gold quality
epithelium of mammary gland	UBERON:0003244	97.73	gold quality
palpebral conjunctiva	UBERON:0001812	97.71	gold quality
ganglionic eminence	UBERON:0004023	97.71	gold quality
cortical plate	UBERON:0005343	97.70	gold quality
tongue squamous epithelium	UBERON:0006919	97.70	gold quality
squamous epithelium	UBERON:0006914	97.69	gold quality
nephron tubule	UBERON:0001231	97.54	gold quality
upper leg skin	UBERON:0004262	97.48	gold quality
seminal vesicle	UBERON:0000998	97.44	gold quality
paraflocculus	UBERON:0005351	97.41	gold quality
pigmented layer of retina	UBERON:0001782	97.34	gold quality
ventricular zone	UBERON:0003053	97.26	gold quality
endothelial cell	CL:0000115	97.24	gold quality
adult organism	UBERON:0007023	97.23	gold quality
superficial temporal artery	UBERON:0001614	97.07	gold quality
mammary gland	UBERON:0001911	96.89	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	21.33
E-GEOD-99795	no	68.17
E-CURD-112	no	2.52

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, AR, BACH1, ESR1, FOXA1, FOXO1, FOXO3, FOXO4, GLI2, MYC, OTX2, SMAD2, SMAD3, SMAD4, SP1, TP53, ZEB1

miRNA regulators (miRDB)

215 targeting CCNG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797

Literature-anchored findings (GeneRIF, showing 39)

• cyclin G2 also associates with various PP2A B’ regulatory subunits, as previously shown for cyclin G1 (PMID:11956189)
• ectopic expression of cyclin G2 inhibits cell proliferation (PMID:12452053)
• Involved in progression and regulation of telomerase (PMID:16364039)
• Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter (PMID:16608856)
• Cyclin G2 may modulate the cell cycle and cellular division processes through modulation of PP2A and centrosomal associated activities. (PMID:17123511)
• Cyclin G2 expression is modulated by HER2 signaling through multiple pathways including phosphoinositide 3-kinase, c-jun NH(2)-terminal kinase, and mTOR signaling. (PMID:18025271)
• our results suggest that cotylenin A and rapamycin induce inhibition of cancer cell growth through the induction of cyclin G2. (PMID:18754885)
• The antiproliferative effect of Nodal/ALK7 on ovarian cancer cells is in part mediated by cyclin G2. (PMID:18784254)
• Cyclin G2 appears to be a negative cell-cycle regulator in gastric cancer, and its expression seems to be inversely related to gastric cancer progression. (PMID:19559447)
• These findings showed that Nodal signaling promotes cyclin G2 transcription by upregulating FoxO3a expression, inhibiting FoxO3a phosphorylation and enhancing its synergistic interaction with Smads. (PMID:21532621)
• Expression of cyclin G1 and G2 is strongly associated with nasopharyngeal carcinoma cell differentiation. (PMID:21688120)
• Our results suggest that CycG2 contributes to DNA damage-induced G(2)/M checkpoint by enforcing checkpoint inhibition of CycB1-Cdc2 complexes. (PMID:22589537)
• These findings show that FOXA1, but not ER- alpha, is essential for AHR(aryl hydrocarbon receptor) -dependent regulation of CCNG2(cyclin G2 ), assigning a role for FOXA1 in AHR action. (PMID:22596188)
• Regulation of cyclin G2 is a key mechanism whereby insulin, insulin analogues and IGF-I stimulate cell proliferation. (PMID:24059861)
• CCNG2 expression decreased in gastric cancer and correlated significantly T stages, lymph node metastasis, clinical stage, histological grade, and poor overall survival (PMID:24248541)
• CCNG2 may play important roles as a negative regulator to kidney cancer ACHN cell by promoting degradation of CDK2. (PMID:24272084)
• Low CCNG2 expression is associated with thyroid cancer. (PMID:24289643)
• CCNG2 expression decreased in prostate cancer and correlated significantly with lymph node metastasis, clinic stage, and Gleason score. (PMID:24293374)
• CCNG2 may play important roles as a negative regulator to esophageal cancer cell by promoting degradation of CDK2. (PMID:24297335)
• The level of CCNG2 was correlated with T stages, lymph node metastasis, clinic stage, and histological grade (P < 0.05) in colorectal carcinoma. (PMID:24307622)
• Cyclin G2-involved invasion in vitro and in vivo. (PMID:24339739)
• Data shows the human CCNG2 and CDK4 expression of visceral adipose tissue are inversely associated with glucose and insulin resistance. (PMID:24708911)
• miR-1246 expression was associated with chemoresistance and CSC-like properties via CCNG2, and could predict worse prognosis in pancreatic cancer patients (PMID:25117811)
• Data (from studies using BeWo cells, a choriocarcinoma cell line, as model of placentation) suggest that miR-378a-5p (microRNA 378a) inhibits cell differentiation in syncytiotrophoblasts, in part, by down-regulating CCNG2 (cyclin G2) expression. (PMID:25122062)
• miR-93-CCNG2 axis may be involved in Laryngeal squamous cell carcinoma proliferation and progression. (PMID:25309979)
• Neisseria meningitidis caused changes in the abundance of several cell cycle regulatory mRNAs, including the cell cycle inhibitors p21(WAF1/CIP1) and cyclin G2 in human brain microvascular endothelial cells. (PMID:26149128)
• Upregulation of miR1246 mediated the malignant progression of colorectal cancer and is partly attributed to the downregulation of the expression of CycG2. (PMID:26573378)
• Taken together, our novel findings demonstrate that cyclin G2 has potent tumor-suppressive effects in Epithelial ovarian cancer (EOC) by inhibiting EMT through attenuating Wnt/beta-catenin signaling. (PMID:26876206)
• CCNG2 knockdown eradicated the effects of miR-340 silencing. (PMID:27374211)
• CycG2 contributes to signaling networks that limit breast cancer. (PMID:27753529)
• EGF-induced, calpain-mediated proteolysis contributes to the rapid destruction of cyclin G2 and that the PEST domain is critical for EGF/calpain actions (PMID:28640887)
• This study demonstrates that cyclin G2 suppresses Wnt/beta-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1. (PMID:30547803)
• these results suggest that miR-590-3p promotes ovarian cancer development, in part by directly targeting CCNG2 and FOXO3. (PMID:31013711)
• MiR-1290 targets CCNG2 to promote the metastasis of oral squamous cell carcinoma. (PMID:31841213)
• Cyclin G2 regulates canonical Wnt signalling via interaction with Dapper1 to attenuate tubulointerstitial fibrosis in diabetic nephropathy. (PMID:31978940)
• Cyclin G2 Is Involved in the Proliferation of Placental Trophoblast Cells and Their Interactions with Endothelial Cells. (PMID:32941407)
• Cyclin G2 upregulation impairs migration, invasion, and network formation through RNF123/Dvl2/JNK signaling in the trophoblast cell line HTR8/SVneo, a possible role in preeclampsia. (PMID:33205477)
• Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma. (PMID:34452627)
• miR-17-5p drives G2/M-phase accumulation by directly targeting CCNG2 and is related to recurrence of head and neck squamous cell carcinoma. (PMID:34598688)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccng2	ENSDARG00000017602
mus_musculus	Ccng2	ENSMUSG00000029385
rattus_norvegicus	Ccng2	ENSRNOG00000002089
drosophila_melanogaster	CycA	FBGN0000404
drosophila_melanogaster	CycB	FBGN0000405
drosophila_melanogaster	CycD	FBGN0010315
drosophila_melanogaster	CycE	FBGN0010382
caenorhabditis_elegans		WBGENE00000863
caenorhabditis_elegans		WBGENE00000864
caenorhabditis_elegans		WBGENE00000865
caenorhabditis_elegans		WBGENE00000866
caenorhabditis_elegans	cyb-2.2	WBGENE00000867
caenorhabditis_elegans		WBGENE00000870
caenorhabditis_elegans	cye-1	WBGENE00000871
caenorhabditis_elegans		WBGENE00017259

Paralogs (18): CCNE1 (ENSG00000105173), CCNP (ENSG00000105219), CCNJ (ENSG00000107443), CCND1 (ENSG00000110092), CCND3 (ENSG00000112576), CCNG1 (ENSG00000113328), CCNI (ENSG00000118816), CCND2 (ENSG00000118971), CCNA1 (ENSG00000133101), CCNB1 (ENSG00000134057), CCNJL (ENSG00000135083), CCNA2 (ENSG00000145386), CCNB3 (ENSG00000147082), CCNO (ENSG00000152669), CCNB2 (ENSG00000157456), CCNF (ENSG00000162063), CCNE2 (ENSG00000175305), CCNI2 (ENSG00000205089)

Protein

Protein identifiers

Cyclin-G2 — Q16589 (reviewed: Q16589)

All UniProt accessions (2): Q16589, D6RHI3

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in growth regulation and in negative regulation of cell cycle progression.

Subcellular location. Cytoplasm.

Tissue specificity. High levels in cerebellum, thymus, spleen and prostate. Low levels in skeletal muscle.

Induction. Activated by actinomycin-D induced DNA damage.

Similarity. Belongs to the cyclin family. Cyclin G subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q16589-1	1	yes
Q16589-2	2

RefSeq proteins (1): NP_004345* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR039361	Cyclin	Family

Pfam: PF00134

UniProt features (7 total): sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16589-F1	80.23	0.52

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-9617828	FOXO-mediated transcription of cell cycle genes
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9614085	FOXO-mediated transcription

MSigDB gene sets: 409 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, AAGCAAT_MIR137, KOBAYASHI_EGFR_SIGNALING_24HR_UP, WANG_CLIM2_TARGETS_UP, JI_RESPONSE_TO_FSH_UP, TGCGCANK_UNKNOWN, HARRIS_HYPOXIA, HOFMANN_CELL_LYMPHOMA_UP, SHEPARD_CRASH_AND_BURN_MUTANT_UP, AAGCCAT_MIR135A_MIR135B, GOBP_CELL_CYCLE_PHASE_TRANSITION, HOEGERKORP_CD44_TARGETS_TEMPORAL_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, FOXO1_01, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP

GO Biological Process (3): G1/S transition of mitotic cell cycle (GO:0000082), cell division (GO:0051301), regulation of cell cycle (GO:0051726)

GO Molecular Function (1): cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538)

GO Cellular Component (3): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
FOXO-mediated transcription	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
cellular process	1
cell cycle	1
regulation of cellular process	1
cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein kinase regulator activity	1
serine/threonine protein kinase complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2184 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNG2	CCNL2	Q96S94	813
CCNG2	TP53	P04637	606
CCNG2	CDK10	Q15131	597
CCNG2	MDM2	Q00987	595
CCNG2	CCNH	P51946	518
CCNG2	CCND3	P30281	514
CCNG2	BMI1	P35226	509
CCNG2	R4GMX3	R4GMX3	509
CCNG2	CCNC	P24863	488
CCNG2	BHLHE41	Q9C0J9	476
CCNG2	CCND1	P24385	471
CCNG2	BTG2	P78543	470
CCNG2	GADD45A	P24522	470
CCNG2	CDKN1A	P38936	470
CCNG2	CCND2	P30279	451

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CCNG2	E7	psi-mi:“MI:0915”(physical association)	0.370
CCNG2	NRIP2	psi-mi:“MI:0915”(physical association)	0.370
CCNG2	NME2	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): FAM208B (Two-hybrid), EFHC2 (Two-hybrid), PPP2R5D (Affinity Capture-MS), NME2 (Affinity Capture-MS), PPP2R5C (Affinity Capture-MS), PPP2R5E (Affinity Capture-MS), CCNG2 (Affinity Capture-RNA), TCF7L2 (Two-hybrid), CCNG2 (Two-hybrid), PPP2R5B (Affinity Capture-Western), PPP2R5C (Affinity Capture-Western), CCNG2 (Affinity Capture-Western), PPP2CA (Reconstituted Complex), NME2 (Affinity Capture-MS), PPP2R5C (Affinity Capture-MS)

ESM2 similar proteins: A5PK16, O08918, O42575, O96020, P24385, P24864, P25322, P30279, P30280, P30282, P39948, P39949, P39950, P41002, P47794, P48961, P49706, P49707, P50755, P50756, P51944, P51945, P51959, P53782, P55169, Q04827, Q0P5D3, Q16589, Q2KI22, Q32NJ2, Q32NM1, Q52QT8, Q5E9I1, Q5E9K7, Q5R5D0, Q5R6J5, Q5SRT8, Q5T5M9, Q5XGG5, Q61457

Diamond homologs: O08918, P13351, P24868, P24869, P25011, P25012, P25322, P30183, P30278, P30279, P30280, P39950, P46277, P46278, P51945, P51959, Q04827, Q0JIF2, Q0P5D3, Q14094, Q16589, Q39068, Q39069, Q52QT8, Q5E9I1, Q5R5D0, Q61456, Q6AY13, Q6ZMN8, Q8WNW2, Q92161, Q95TJ9, Q9Z2V9, A2YH60, O96020, P04962, P24385, P30281, P30282, P34800

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	26
Likely benign	1
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

1022 predictions. Top by Δscore:

Variant	Effect	Δscore
4:77158667:GGAG:G	donor_gain	1.0000
4:77158668:GAG:G	donor_gain	1.0000
4:77158668:GAGG:G	donor_gain	1.0000
4:77158670:GGTA:G	donor_loss	1.0000
4:77158671:G:GA	donor_loss	1.0000
4:77158671:G:GG	donor_gain	1.0000
4:77158672:T:G	donor_loss	1.0000
4:77159360:A:AG	acceptor_gain	1.0000
4:77159362:TGCA:T	acceptor_loss	1.0000
4:77159363:GCA:G	acceptor_loss	1.0000
4:77159364:CA:C	acceptor_loss	1.0000
4:77159365:A:AG	acceptor_gain	1.0000
4:77159365:AGAAT:A	acceptor_gain	1.0000
4:77159366:G:GG	acceptor_gain	1.0000
4:77159366:GA:G	acceptor_gain	1.0000
4:77159366:GAA:G	acceptor_gain	1.0000
4:77159366:GAAT:G	acceptor_gain	1.0000
4:77159366:GAATG:G	acceptor_gain	1.0000
4:77159504:GGTA:G	donor_loss	1.0000
4:77159506:T:G	donor_loss	1.0000
4:77160830:G:GG	donor_gain	1.0000
4:77160834:GT:G	donor_gain	1.0000
4:77160864:G:GT	donor_gain	1.0000
4:77160904:G:GT	donor_gain	1.0000
4:77160908:C:G	donor_gain	1.0000
4:77161471:A:AG	acceptor_gain	1.0000
4:77161471:ATT:A	acceptor_gain	1.0000
4:77161475:TATA:T	acceptor_loss	1.0000
4:77161476:A:AG	acceptor_gain	1.0000
4:77161476:ATAG:A	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000097436 (4:77161275 T>A,C), RS1000210112 (4:77156996 C>A,T), RS1000242500 (4:77156846 C>T), RS1000278426 (4:77160420 A>C,G), RS1000612531 (4:77159060 C>T), RS1000624755 (4:77156227 G>C), RS1000940662 (4:77165221 G>A), RS1000971765 (4:77164980 G>A), RS1001060202 (4:77158867 G>A,C), RS1001394166 (4:77166124 A>G,T), RS1001502272 (4:77159954 C>T), RS1001617686 (4:77156661 G>A), RS1002034118 (4:77160586 G>A), RS1002201691 (4:77164801 T>C), RS1002348379 (4:77155615 T>C)

Disease associations

OMIM: gene MIM:603203 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008957_1	Hormone measurements	6.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010232	osteocalcin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

151 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	8
Estradiol	affects expression, affects binding, decreases expression, affects cotreatment, increases expression (+2 more)	7
Fluorouracil	affects response to substance, increases expression	5
trichostatin A	affects cotreatment, decreases expression, affects expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Arsenic Trioxide	increases expression, affects cotreatment	4
Cisplatin	increases expression, decreases expression, affects response to substance, affects cotreatment	4
Tetrachlorodibenzodioxin	increases expression, affects binding, increases reaction, affects cotreatment, affects reaction (+2 more)	4
Cyclosporine	decreases expression, increases expression	4
Sirolimus	decreases expression, decreases reaction, affects cotreatment, increases expression	4
cobaltous chloride	increases expression, decreases reaction	3
Oxygen	increases expression	3
bisphenol A	decreases expression, increases expression	2
nickel chloride	increases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	2
Panobinostat	affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, affects cotreatment, increases abundance	2
Benzo(a)pyrene	increases expression, decreases methylation	2
Drugs, Chinese Herbal	increases expression, decreases expression	2
Metformin	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
Niclosamide	decreases expression, decreases reaction, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
Lithium Chloride	decreases expression, increases expression	2
Cadmium Chloride	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SH43	HAP1 CCNG2 (-) 1	Cancer cell line	Male
CVCL_XM55	HAP1 CCNG2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.